Affymetrix and Gene Company Limited are expanding the portfolio to include a range of clinical tests in the area of oncology. These tests may be applicable to patients in Hong Kong pending any clinical validations and approvals as required. We are would like to invite you to hear more about these tests and how they can improve patient care.

**Ikaryos Diagnostics**
*Cancer Clinical Research Applications with Microarrays: Virtual Karyotyping with SNP Arrays*
*Robert Klein, CEO,*

**Pathwork Diagnostics**
*Pathwork Tissue of Origin Test: Identify Metastatic Tumors that are Poorly Differentiated Using FFPE Specimens*
*Dave Craford, Chief Commercial Officer*

**Skyline Diagnostics BV**
*Diagnosis in Acute Myeloid Leukemia: The AMLProfiler and the Art of Distinction*
*Simon Folkertsma, PhD, Business Development*

To join us, please kindly give us a call or reply via email/fax.

Gene Company Limited  Tel: 2897-6221   Fax: 2515-9371/2557-1283   E-mail: sales@genehk.com
Innovative Tools for use in Clinical Cancer Applications

Skyline Diagnostics BV
Diagnosis in Acute Myeloid Leukemia:
The AMLProfiler and the Art of Distinction

The AMLProfiler is a diagnostic microarray based on the Affymetrix® GeneChip® System. This comprehensive test for patients with Acute Myeloid Leukemia (AML) analyzes several relevant diagnostic and prognostic markers simultaneously.

The AMLProfiler combines several technologies on one microarray:
1. Gene expression profiling for detection of inv(16), t(15;17), t(8;21) and CEBPA mutations
2. Genotyping for identification of NPM1 mutations (A,B and D) and
3. Determination of over-expression of several genes with prognostic significance in AML (EVI1, BAALC, ERG and MN1)

The sample workup procedure is highly automated, including the remote analysis of the raw data on a secured server at Skyline and sending the diagnostic results to the requesting laboratory. Using such an automated state-of-the-art test in combination with its underlying solid IT infrastructure will lead to a standardized and cost-effective workflow in the laboratory. However, the ultimate benefit is for the patient, providing in-depth insight in the prognosis of an individual patient with direct consequences for the clinical decision-making process. It will facilitate the physician in the decision of whether or not to perform an allogeneic stem cell transplantation in a patient with AML.

The AMLProfiler was launched in Europe as a diagnostic service in December 2009 and will be offered as an IVD in the fall of 2010. In the US, Skyline is the first company to apply for FDA Pre-Market Approval (PMA) for a diagnostic microarray.

Simon Folkertsma is responsible for Business development at Skyline Diagnostics. He studied molecular biology at the University of Groningen and graduated in 2000. He completed his PhD in 2006 at the Centre for Molecular and Biomolecular Informatics (CMBI, promoter Prof. Dr. Jacob de Vlieg, Organon NV) on his research on nuclear receptors (focus on molecular modeling, cheminformatics, bioinformatics, and data mining). At Organon (Schering Plough), Simon worked in early drug discovery projects and on translational medicine concepts, linking clinical research with early drug discovery by using pharmacovigilance data, eClinical and medical IT solutions. At Skyline, Simon is responsible for the coordination of the CTMM BioCHIP project and business development.

For further information please visit http: www.skyline-diagnostics.nl
Innovative Tools for use in Clinical Cancer Applications

Pathwork Diagnostics
Pathwork Tissue of Origin Test:
Identify Metastatic Tumors that are Poorly Differentiated Using FFPE Specimens

There are clinical and economic benefits to determining the site of origin site in metastatic, poorly differentiated, and undifferentiated tumors. Microarray use has been largely limited to RNA derived from frozen specimens. Pathwork has developed a microarray-based test that measures the expression pattern, comprising 2000 genes, in a tumor to compare it to expression patterns of a panel of 15 known tumor types, representing 58 morphologies and covering 90 percent of all solid tumors. The Pathwork Diagnostics laboratory produces a report with an objective score for each potential tissue. The test uses a proprietary Pathchip® microarray and runs on the proven Affymetrix® GeneChip® System.

The session will include a discussion of the following:

- Challenges in diagnosing metastatic, poorly differentiated, and undifferentiated tumors
- Microarrays and FFPE Specimens
- Tissue of Origin Test: design and performance

Dave Craford is the Chief Commercial Officer of Pathwork Diagnostics. Mr. Craford leads the company’s overall marketing, sales, and customer support strategies and operations. He has 20 years of experience in the life sciences industry with a proven track record for building new markets and establishing market leadership. Prior to joining Pathwork, Mr. Craford was Vice President of Business Development at Affymetrix, Inc., where he held various business development and marketing leadership roles. Prior to Affymetrix, Mr. Craford held senior sales roles at Amersham Life Sciences, Inc., and at BTX, a life sciences instrumentation company. Mr. Craford received a BA in biochemistry and cell biology from the University of California, San Diego, and an MBA with a focus on marketing and finance from the Haas School of Business at the University of California, Berkeley.

For further information please visit

www.pathworkdx.com
Innovative Tools for use in Clinical Cancer Applications

**Ikaryos Diagnostics**
Cancer Clinical Research Applications with Microarrays: Virtual Karyotyping with SNP Arrays

Chromosomal copy number alterations have been used to guide the management of cancer patients for decades, and there are many well-established, clinically validated applications for such techniques. In addition, cancer cells have a propensity to develop copy-neutral loss of heterozygosity (LOH), which is not detectable by conventional karyotyping, array comparative genomic hybridization, or FISH. SNP array karyotyping provides dramatically better resolution than conventional karyotyping, does not require culture, performs well on paraffin-embedded samples, and readily detects copy-neutral LOH, making it a powerful new addition to our molecular oncology tool box. Examples of the clinical impact of SNP array karyotyping will be presented and considerations for routine clinical use of the platform will be discussed.

**Robert Klein, PhD, is the CEO of Ikaryos Diagnostics.** Dr. Klein received his bachelors in biochemistry from the University of California, Berkeley and his PhD in molecular genetics from the Massachusetts Institute of Technology (MIT) in 1993. He completed a post doctoral fellowship at Genentech where he subsequently took a job as a scientist and invented technology that moved the company into the genomics era. Dr. Klein has played a key role at a number of startup companies including Deltagen (a functional genomics company), Rinat Neuroscience (sold to Pfizer), and Amnestix (sold to Sygnis Pharma AG). Dr. Klein founded Ikaryos Diagnostics in 2009.

For further information please visit [www.ikaryos.com](http://www.ikaryos.com)